Tenax’s major holder buys shares over three days (NASDAQ: TENX)

What happened

Adar1 Capital Management, LLC, a 10% owner, bought Tenax Therapeutics, Inc. (NASDAQ: TENX) common stock on 2026-10-19, 2026-10-20 and 2026-10-21. The filing says the purchases totaled 922,849 shares and about $1.46 million.

It reports 336,528 shares on 2026-10-19 at $1.5066 each, 254,342 shares on 2026-10-20 at $1.5952 each and 331,979 shares on 2026-10-21 at $1.6588 each. The filing calls each price a weighted average.

Footnotes say the shares were bought in multiple transactions at price ranges of $1.4300 to $1.5350, $1.5000 to $1.6300 and $1.6200 to $1.6900. After the buying, Adar1 held 7,447,000 shares.

The report names Adar1 Capital Management, LLC and Daniel Schneeberger as the reporting persons. Schneeberger signed the filing on 2026-10-21, the same day as the last purchase.

Key numbers

Metric	Latest	Change	Source
Shares acquired	922,849 shares		SEC Form 4
Purchase value	about $1.46 million		SEC Form 4
Shares held after purchase	7,447,000 shares		SEC Form 4
Weighted average price range	$1.51 to $1.66 a share		SEC Form 4

Read more: Tenax Therapeutics (TENX) stock analysis and investment case

Why it matters

OptimistFi's case is that Tenax is a cash-funded, pre-revenue clinical-stage drug-development bet whose value depends on turning trial evidence into approvable data before burn and dilution consume the upside. This filing strengthens that view because it shows a major holder adding to the position.

The 922,849 shares were about 14.1% of Adar1's pre-trade holding, so the buy was large relative to the existing stake. That gives investors a new ownership baseline for the holder's exposure.

The three purchases spread across 2026-10-19 to 2026-10-21 show accumulation over several sessions rather than one print. The reported prices also rose from $1.5066 to $1.6588 across the window.

It is still an ownership update with weighted-average prices. The filing changes the stake data more than the operating picture, and it does not say anything about trial progress.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next quarterly report is the next test named in OptimistFi's case. Another Form 4 showing more buying would reinforce the signal, while a pause or reversal would weaken it.

This filing now serves as the clean baseline for Adar1's reported exposure. Investors will watch whether later filings keep the stake rising from 7,447,000 shares.

More from OptimistFi

• TENX stock: the Tenax Therapeutics thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps